Jessica Blume - Centene Corp Independent Director
| CNC Stock | USD 74.77 0.04 0.05% |
Director
Ms. Jessica L. Blume is Independent Director of the Company. Ms. Blume was Vice Chairman of Deloitte LLP from 2012 until her retirement in 2015. She served in various leadership positions during her 26 years at Deloitte including serving on the Board of Directors, as the Chair of the Executive Compensation and Evaluation Committee, and a member of the Finance, Governance, Strategic Investment and Risk Committees. Ms. Blume currently serves as a director of Publix Super Markets, Inc. since 2018.
| Age | 66 |
| Tenure | 6 years |
| Address | Centene Plaza, Saint Louis, MO, United States, 63105 |
| Phone | 314 725 4477 |
| Web | https://www.centene.com |
Centene Corp Management Efficiency
The company has Return on Asset of 0.0367 % which means that on every $100 spent on assets, it made $0.0367 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1044 %, implying that it generated $0.1044 on every 100 dollars invested. Centene Corp's management efficiency ratios could be used to measure how well Centene Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Centene Corp's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Centene Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 6.4 B, whereas Net Tangible Assets are projected to grow to (1.4 B).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Kurian | Cigna Corp | 54 | |
| William McDonald | Humana Inc | 64 | |
| Timothy Flynn | UnitedHealth Group Incorporated | 64 | |
| William Weldon | CVS Health Corp | 72 | |
| James OBrien | Humana Inc | 66 | |
| Alecia DeCoudreaux | CVS Health Corp | 66 | |
| Marissa Peterson | Humana Inc | 58 | |
| NancyAnn DeParle | CVS Health Corp | 64 | |
| Steven Orlando | Molina Healthcare | 69 | |
| David Feinberg | Humana Inc | 58 | |
| Siddhartha Sankaran | Oscar Health | 46 | |
| Karen Katz | Humana Inc | 64 | |
| William Ballard | UnitedHealth Group Incorporated | 77 | |
| Gail Wilensky | UnitedHealth Group Incorporated | 76 | |
| Donna Zarcone | Cigna Corp | 63 | |
| Garrey Carruthers | Molina Healthcare | 80 | |
| David Jones | Humana Inc | 71 | |
| Daniel Cooperman | Molina Healthcare | 70 | |
| Fernando Aguirre | CVS Health Corp | 64 | |
| Richard Zoretic | Molina Healthcare | 62 | |
| Valerie Rice | UnitedHealth Group Incorporated | 58 | |
Management Performance
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0367 |
Centene Corp Leadership Team
Elected by the shareholders, the Centene Corp's board of directors comprises two types of representatives: Centene Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Centene. The board's role is to monitor Centene Corp's management team and ensure that shareholders' interests are well served. Centene Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Centene Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rich Fisher, Senior Vice President, Medicare Chief Executive Officer | ||
| Brent Layton, Executive Vice President, President - Health plans, Products, and International | ||
| Colin Toney, Executive Vice President - Mergers and Acquisitions | ||
| H Dallas, Acting Chairman of the Board, Lead Independent Director | ||
| Michael Neidorff, Chairman of the Board, President, Chief Executive Officer | ||
| Richard Gephardt, Independent Director | ||
| Katie Casso, Senior Vice President, Corporate Controller and Chief Accounting Officer | ||
| Leslie Norwalk, Independent Director | ||
| Jim Murray, Chief Transformation Officer | ||
| Kenneth Fasola, President | ||
| Jeffrey Schwaneke, Senior Vice President Chief Accounting Officer, Corporate Controller | ||
| David Steward, Independent Director | ||
| Christopher Koster, Executive Vice President, General Counsel, Company Secretary | ||
| Lori Robinson, Independent Director | ||
| Suzy DePrizio, Senior Vice President Chief Marketing Officer | ||
| Shannon Susko, Senior Officer | ||
| Thomas Thompson, Independent Director | ||
| Jesse Hunter, Executive Vice President - Mergers and Acquisitions, Chief Strategy Officer | ||
| Robert Ditmore, Presiding Independent Director | ||
| William Trubeck, Independent Director | ||
| Jonathan Dinesman, Executive Vice President - Government Relations | ||
| Mark Brooks, Executive Vice President, Chief Information Officer | ||
| Kenneth Burdick, Executive Vice President - Markets & Products | ||
| Robert Sanders, Executive Resources | ||
| Christopher Coughlin, Independent Director | ||
| Jennifer Gilligan, Senior Vice President of Investor Relations | ||
| Frederick Eppinger, Independent Director | ||
| H Sanders, Executive Vice President - Global Human Resources | ||
| Theodore Samuels, Independent Director | ||
| Sarah London, President - Health Care Enterprises and Executive Vice President - Advanced Technology | ||
| Brandy Burkhalter, Chief Operating Officer, Executive Vice President | ||
| Orlando Ayala, Independent Director | ||
| Jessica Blume, Independent Director | ||
| Brian MBA, Chief Officer | ||
| Keith Williamson, Executive Vice President General Counsel, Secretary | ||
| Shannon Bagley, Executive Vice President, Chief Administrative Officer | ||
| Wayne DeVeydt, Independent Director | ||
| Tommy Thompson, Independent Director | ||
| Christopher Isaak, Senior Vice President Corporate Controller and Chief Accounting Officer | ||
| Susan Smith, Chief Officer | ||
| David Thomas, Executive Vice President - Marketing | ||
| John Roberts, Independent Director | ||
| Andrew Asher, Chief Financial Officer, Executive Vice President | ||
| Ashlee Knuckey, Chief Officer |
Centene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Centene Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0367 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 38.36 B | ||||
| Shares Outstanding | 533.66 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 7.59 M | ||||
| Price To Earning | 20.27 X |
Pair Trading with Centene Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Centene Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Centene Corp will appreciate offsetting losses from the drop in the long position's value.Moving against Centene Stock
| 0.76 | INSP | Inspire Medical Systems Financial Report 7th of May 2024 | PairCorr |
| 0.57 | EHC | Encompass Health Corp | PairCorr |
| 0.54 | GKOS | Glaukos Corp | PairCorr |
| 0.48 | DXCM | DexCom Inc | PairCorr |
The ability to find closely correlated positions to Centene Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Centene Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Centene Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Centene Corp to buy it.
The correlation of Centene Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Centene Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Centene Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Centene Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centene Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Centene Stock refer to our How to Trade Centene Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Centene Stock analysis
When running Centene Corp's price analysis, check to measure Centene Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centene Corp is operating at the current time. Most of Centene Corp's value examination focuses on studying past and present price action to predict the probability of Centene Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centene Corp's price. Additionally, you may evaluate how the addition of Centene Corp to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Centene Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centene Corp. If investors know Centene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centene Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Earnings Share 5.07 | Revenue Per Share 264.738 | Quarterly Revenue Growth 0.044 | Return On Assets 0.0367 |
The market value of Centene Corp is measured differently than its book value, which is the value of Centene that is recorded on the company's balance sheet. Investors also form their own opinion of Centene Corp's value that differs from its market value or its book value, called intrinsic value, which is Centene Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centene Corp's market value can be influenced by many factors that don't directly affect Centene Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centene Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Centene Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centene Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.